March 24, 2021
JPMA President Joji Nakayama The Japan Pharmaceutical Manufacturers Association (JPMA) has incorporated a post-launch mechanism that could be described as “innovation re-pricing” in its policy proposal in 2021, calling for the re-evaluation of medicines that are on the market after...read more